Description

Compound 7P Nootropic Powder

 

 

 

CAS Number	1890208-58-8
Other Names	Acetamide, 2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl)-
IUPAC	2-(2-methoxy-N-(4-methylphenyl)sulfonylanilino)-N-(4-methoxypyridin-3-yl)acetamide
Molecular Formula	C₂₂H₂₃N₃O₅S
Molecular Weight	441.5
Purity	≥99% Pure (LC-MS)
Liquid Availability	30mL liquid (50mg/mL, 1500mg bottle)
Powder Availability	1 gram
Gel Availability	N/A
Storage	Store in a dry, cool, dark place. For best preservation, store at 4°C or colder away from bright light.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

Compound 7P and Axonal Regeneration

Compound 7P is a nootropic compound originally developed to assist in neurite outgrowth and cognitive enhancement. Compound 7P is currently being researched to determine the role it could potentially play in terms of axon regeneration. Degeneration of axons can occur for a number of reasons, most common being trauma or injury, neurological diseases, and aging. Unfortunately, once the neurons are damaged they cannot repair themselves or regenerate without additional assistance.

Some of the most common methods of growth promotion focus on understanding the specific mechanisms of action and the manipulation of various signaling pathways. The most prevalent mechanisms typically involve epigenetic regulation of gene transcription, development-dependent transcription, and the mTOR and STAT3 signaling pathways. Researchers Park et. Al have discovered that altering the expression of these pathways can effectively lead to axon regeneration in the CNS.

Building off the work of Park et. Al, Ku et. Al have attempted to find additional modalities that will result in axon growth. The research team was able to visually assess and measure all in vitro neurite outgrowth through the use of phenotypic cell-based screens. It’s important to note that using these phenotypic small screen methods of measurement allow researchers to identify different types of protein targets and explain the mechanisms of various signaling pathways. Furthermore, being able to track axon elongation via phenotypic small screen provides an opportunity to more accurately pharmacologically manipulate the different factors assisting axon regeneration.

 

Use of Compound 7P to Promote Optic Nerve Regeneration

The research team of Ku et. Al was able to use phenotypic screening in order to identify compound 7P. They concluded that compound 7P was able to improve neurite outgrowth in the primary neurons of the hippocampus, cerebral cortex, and retina. Further testing found that in animal models, compound 7P was able to induce regeneration of the optic nerves in cases of injury.

The study initially began with treating retina neuronal cells with doses of either 2 or 20 μM of compound 7P. The cells were then incubated for 72 hours and treated with paraformaldehyde and an anti-neurofilament antibody in order to identify and measure axonal changes. During observation of the cultures the researchers were able to measure cell body size and morphology in order to identify retinal ganglion cells (RGCs). That being said, results of this initial study found that compound 7P led to significant axon growth. Axonal growth increased the most when the cells were treated with a 10 μM dose of the compound.

The second portion of the study was to determine if treatment with compound 7P would elicit the same effect in the RGCs of injured optic nerves as it did in healthy RGCs. The crushed optic nerves were treated with either a placebo, or a daily dose of 0.22 μg per eye, for 3 weeks. Following treatment, the animals were euthanized and cross sections of the optic nerves were stained with an anti-GAP43 antibody so researchers could efficiently identify and measure axonal growth. Results found that when the crushed optic nerves were treated with compound 7P the axons grew remarkably farther past the lesion epicenter than the nerves treated with a placebo. The results of this study suggest that further research should be conducted in order to determine how compound 7P can potentially increase axon growth and treat neuronal damage throughout the central nervous system (https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00015#).

 

Effects of Compound 7P Against Cervical Cancer

In addition to its ability to promote axonal regeneration, researchers Wang et. Al examined the potential of compound 7P to combat cervical cancer. The researchers originally hypothesized that electron-withdrawing substituents, such as compound 7P, have more potent anti-cancer qualities than electron-donating groups. Results of the study were based on the histological assessment of a mouse xenograft model inoculated with HeLa cells. It was reported that compound 7P exhibited the highest anti-cancer activity by actively inhibiting the growth of cervical tumors. Excision of the tumor-bearing tissue revealed that compound 7P improved the overall microstructure of the tissue. Furthermore, compound 7P effectively increased the amount of HeLa cells in G0/G1 and S-phases of the cell cycle while decreasing the amount of cells in the G3/M phases. Overall, this suggests the potential to activate more anti-cancer HeLa cells, however, more research should be conducted in order to determine the most effective dose (https://pubmed.ncbi.nlm.nih.gov/29068538/).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

Compound 7P is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

File Name	View/Download
08-30-2023-Umbrella-Labs-Compound-7P-Certificate-Of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)

 

 

Additional information

Weight	1 oz
Dimensions	0.5 × 0.5 × 1 in
Options	30mL Liquid 50mg/mL 1500mg Bottle, 500 Milligrams Powder